Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 3/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.34 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3773208 | 0.90 | CHEK1 (0.40) | RXRARXRB | |
| SCHEMBL3779611 | 0.85 | RXRA (0.35) | RXRANR1H2NR1H3ALOX5APRXRB | |
| SCHEMBL3767931 | 0.85 | RXRA (0.36) | RXRANR1H2NR1H3MRGPRX4RXRB | |
| SCHEMBL3147123 | 0.85 | PTGER1 (0.35) | RXRANR1H2NR1H3RXRBPTPN11 | |
| SCHEMBL3781094 | 0.83 | KMO (0.38) | KMORXRANR1H2NR1H3ALOX5AP | |
| SCHEMBL3146952 | 0.78 | CHRNB2 (0.44) | — | |
| SCHEMBL28929747 | 0.78 | RXRA (0.41) | RXRARXRBNR4A2NR4A1NR4A3 | |
| SCHEMBL3151919 | 0.77 | CYP11B1 (0.42) | LMNA | |
| SCHEMBL3137070 | 0.77 | XDH (0.43) | — | |
| SCHEMBL7605146 | 0.77 | CHRNB2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | LES LABORATOIRES SERVIER (FR) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317698-A1 | Polysubstituted Pyridinylaminoalkylene- and Pyridinyloxyalkylene-Cyclopropanamine Compounds, a Process for Their Preparation and Pharmaceutical Compositions Containing Them | CHRNA6, CHRNE, CHRNG | KMO 1244/4885RXRA 38/4885NR1H2 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.